|
Plasminogen Activator Inhibitor-1 Deficiency
|
0.700 |
Biomarker
|
disease |
CTD_human |
|
|
|
|
Plasminogen Activator Inhibitor-1 Deficiency
|
0.700 |
Biomarker
|
disease |
GENOMICS_ENGLAND |
|
|
|
|
TRANSCRIPTION OF PLASMINOGEN ACTIVATOR INHIBITOR, MODULATOR OF
|
0.300 |
Biomarker
|
phenotype |
GENOMICS_ENGLAND |
|
|
|
|
Menorrhagia
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
|
Tumor Progression
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
<b>Conclusions:</b> KRAS-mutant pancreatic cancer cells can activate PSCs through PAI-1/LRP-1 signaling to promote fibrosis and cancer progression.
|
31695760 |
2019 |
|
Helicobacter pylori (H. pylori) infection in conditions classified elsewhere and of unspecified site
|
0.040 |
Biomarker
|
disease |
BEFREE |
<i>Helicobacter pylori colonizes</i> the stomach in about half of the world's population.<i>H. pylori</i> strains containing the <i>cag</i> pathogenicity island (<i>cag</i> PAI) are associated with a higher risk of gastric adenocarcinoma or peptic ulcer disease compared to <i>cag</i> PAI-negative strains.
|
31712269 |
2020 |
|
Peptic Ulcer
|
0.050 |
GeneticVariation
|
disease |
BEFREE |
<i>Helicobacter pylori colonizes</i> the stomach in about half of the world's population.<i>H. pylori</i> strains containing the <i>cag</i> pathogenicity island (<i>cag</i> PAI) are associated with a higher risk of gastric adenocarcinoma or peptic ulcer disease compared to <i>cag</i> PAI-negative strains.
|
31712269 |
2020 |
|
Gastric Adenocarcinoma
|
0.040 |
GeneticVariation
|
disease |
BEFREE |
<i>Helicobacter pylori</i> colonizes about half of humans worldwide, and its presence in the gastric mucosa is associated with an increased risk of gastric adenocarcinoma, gastric lymphoma, and peptic ulcer disease.<i>H. pylori</i> strains carrying the <i>cag</i> pathogenicity island (<i>cag</i>PAI) are associated with increased risk of disease progression.
|
31088930 |
2019 |
|
Peptic Ulcer
|
0.050 |
GeneticVariation
|
disease |
BEFREE |
<i>Helicobacter pylori</i> colonizes about half of humans worldwide, and its presence in the gastric mucosa is associated with an increased risk of gastric adenocarcinoma, gastric lymphoma, and peptic ulcer disease.<i>H. pylori</i> strains carrying the <i>cag</i> pathogenicity island (<i>cag</i>PAI) are associated with increased risk of disease progression.
|
31088930 |
2019 |
|
Tumor Cell Invasion
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
(-)-Epigallocatechin gallate derivatives reduce the expression of both urokinase plasminogen activator and plasminogen activator inhibitor-1 to inhibit migration, adhesion, and invasion of MDA-MB-231 cells.
|
30009577 |
2018 |
|
PAI-1 4G/5G polymorphism
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
(1) Plasma PAI-1 level was elevated in Type 2 diabetic patients; (2) The level of plasma PAI-1 is closely related to PAI-1 gene 4G/5G polymorphism and (3) PAI-1 4G/5G polymorphism is associated with the development and progression of predominant proteinuria diabetes nephropathy.
|
26616527 |
2016 |
|
Kidney Diseases
|
0.100 |
AlteredExpression
|
group |
BEFREE |
(1) Plasma PAI-1 level was elevated in Type 2 diabetic patients; (2) The level of plasma PAI-1 is closely related to PAI-1 gene 4G/5G polymorphism and (3) PAI-1 4G/5G polymorphism is associated with the development and progression of predominant proteinuria diabetes nephropathy.
|
26616527 |
2016 |
|
Diabetes Mellitus
|
0.300 |
AlteredExpression
|
group |
BEFREE |
(1) The plasma PAI-1 levels of group A (60.39 ± 17.01 ng/L), group B (68.76 ± 17.81 ng/L) and group C and (68.63 ± 18.30 ng/L) are higher than that of controls (46.26 ± 26.04 ng/L); (2) Patients with genotype 4G/4G tended to exhibit higher PAI-1 level; (3) The distribution frequency of genotype 4G/4G in group C was significantly higher than in group A (42.4% vs. 28.7%, p < 0.05) and (4) In type 2 diabetic patients, the occurrence of diabetes nephropathy in genotype 4G/4G, 4G/5G and 5G/5G is 35.0%, 30.2% and 21.4%, respectively.
|
26616527 |
2016 |
|
Diabetes
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
(1) The plasma PAI-1 levels of group A (60.39 ± 17.01 ng/L), group B (68.76 ± 17.81 ng/L) and group C and (68.63 ± 18.30 ng/L) are higher than that of controls (46.26 ± 26.04 ng/L); (2) Patients with genotype 4G/4G tended to exhibit higher PAI-1 level; (3) The distribution frequency of genotype 4G/4G in group C was significantly higher than in group A (42.4% vs. 28.7%, p < 0.05) and (4) In type 2 diabetic patients, the occurrence of diabetes nephropathy in genotype 4G/4G, 4G/5G and 5G/5G is 35.0%, 30.2% and 21.4%, respectively.
|
26616527 |
2016 |
|
Lobar Pneumonia
|
0.010 |
Biomarker
|
disease |
BEFREE |
(3) PAI-1 gene-deficient mice, however, had an unaltered immune response to pneumococcal pneumonia, as measured by cell recruitment into lungs, bacterial outgrowth, and survival.
|
12702502 |
2003 |
|
Streptococcal pneumonia
|
0.010 |
Biomarker
|
disease |
BEFREE |
(3) PAI-1 gene-deficient mice, however, had an unaltered immune response to pneumococcal pneumonia, as measured by cell recruitment into lungs, bacterial outgrowth, and survival.
|
12702502 |
2003 |
|
Myocardial Infarction
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
05), total cholesterol (OR 1.35, 95% CI 1.11 to 1.65), plasminogen activator inhibitor-1 4G/4G (OR 1.72, 95% CI 1.20 to 2.45), and CRP levels >0.33 mg/L (OR 1.75, 95% CI 1.05 to 2.91) were all independently associated with a positive family history of myocardial infarction.
|
10634818 |
2000 |
|
Polycystic Ovary Syndrome
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
2) PCOS women have higher levels of PAI-1 compared with the control group.
|
15191349 |
2004 |
|
Polycystic Ovary Syndrome
|
0.100 |
GeneticVariation
|
disease |
LHGDN |
2) PCOS women have higher levels of PAI-1 compared with the control group.
|
15191349 |
2004 |
|
Tumor Cell Invasion
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
273H cells also showed markedly increased in vitro invasion and migration potentials, and displayed reduced Maspin, PAI-1, and KAI1 mRNA expressions as compared with 213Q and wt cells.
|
17636407 |
2007 |
|
Liver regeneration disorder
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
3 In vitro, GW6604 inhibited autophosphorylation of ALK5 with an IC(50) of 140 nM and in a cellular assay inhibited TGF-beta-induced transcription of PAI-1 (IC(50): 500 nM).In vivo, GW6604 (40 mg kg(-1) p.o.) increased liver regeneration in TGF-beta-overexpressing mice, which had undergone partial hepatectomy.
|
15723089 |
2005 |
|
Acute myocardial infarction
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
4G carriership of the polymorphism of PAI-1 was associated with lower risk for acute MI (odds ratio 0.45, 95% confidence interval 0.23-0.88, P = 0.02) after adjusting for major cardiovascular risk factors.
|
19844663 |
2010 |
|
Pneumonia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
4G/5G plasminogen activator inhibitor-1 polymorphisms and haplotypes are associated with pneumonia.
|
17761618 |
2007 |
|
Lupus Nephritis
|
0.070 |
GeneticVariation
|
disease |
BEFREE |
4G/5G plasminogen activator inhibitor-1 and -308 A/G tumor necrosis factor-α promoter gene polymorphisms in Argentinean lupus patients: focus on lupus nephritis.
|
23143392 |
2014 |
|
Polycystic Ovary Syndrome
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
4G/5G polymorphism of PAI-1 gene and Alu-repeat I/D polymorphism of TPA gene in Turkish patients with polycystic ovary syndrome.
|
17661167 |
2007 |